NASDAQ:COCP

Biotechnology·Finance·NASDAQ:COCP·News·Stock Market

Cocrystal Pharma Moves Lower as Norovirus Program Draws Fresh Attention

Cocrystal Pharma shares slipped to $1.11 in light Nasdaq trading Thursday as investors awaited results from its Phase 1b norovirus study. The company reported $4.7 million in cash at March 31 and a going-concern warning in its latest 10-Q. Market value stood at $15.3 million, with fewer than 20,000 shares traded by late morning.

May 21, 2026

Top 2 ASX Shares to Buy and Hold for the Next Decade
May 29, 2026, 8:30 PM EDT. Two ASX shares stand out for long-term growth potential: Lovisa Holdings Ltd (ASX: LOV) and the Global X S&P World Ex Australia GARP ETF (ASX: GARP). Lovisa, a fast-growing affordable jewellery retailer, is expanding its global footprint with a 6.3% store increase recently, boosted by strong 20% revenue and profit growth. Its valuation stands at under 19 times estimated FY28 earnings per share, signaling potential value. Meanwhile, the GARP ETF invests in 250 global companies with growth-at-a-reasonable-price traits, targeting firms with solid sales, earnings, attractive price/earnings ratios, and strong financial quality, positioning it for potential market-beating returns. These choices reflect solid growth and value strategies aimed at outperforming the S&P/ASX 200 Index over the next decade.